logo
China is building a giant laser to generate the energy of the stars, satellite images appear to show

China is building a giant laser to generate the energy of the stars, satellite images appear to show

CNN05-02-2025

Images from space reveal an enormous X-shaped building rising up from rocky terrain in southwestern China. This is a huge nuclear fusion research facility, analysts say, and it could be a sign China is leaping ahead in the quest to harness this futuristic energy source.
It could also mean they are amping up nuclear weapons development.
Decker Eveleth, an analyst at US-based research organization the CNA Corporation, has been among those watching this facility for years. In 2020, a US official released images purporting to show various potential Chinese nuclear locations, including the site near Mianyang in Sichuan province.
At this point, it was basically 'a patch of dirt,' Eveleth told CNN. But after Covid shutdowns were lifted, construction accelerated. The project is described as a 'laser fusion' facility in contract documents obtained by Eveleth and seen by CNN.
If the facility is indeed a laser facility, it will offer a unique way of studying materials in extreme conditions. It allows scientists to create 'pressures that are typically found in the center of stars or in nuclear weapons,' said Brian Appelbe, a research fellow from the Centre for Inertial Fusion Studies at Imperial College London.
Eveleth says the four giant arms shown in the satellite image are 'bays' which will be able to shoot lasers at the tall, central tower, which houses a target chamber containing hydrogen isotopes. The laser energy fuses the hydrogen together to create a burst of energy in a process called ignition.
Nuclear fusion offers the tantalizing prospect of abundant, clean energy without the long-lived radioactive waste problem of nuclear fission, the world's current nuclear energy technology. Countries and companies across the world are in a race to master it.
The US has long been a leader. The National Ignition Facility in California, which also uses laser-ignition technology, made a huge fusion energy breakthrough in 2022. In a world first, NIF scientists achieved a successful nuclear fusion reaction with a net energy gain (although they didn't count the energy needed to power the lasers).
It was a big step forward in the decades-long quest to recreate on Earth the reaction which powers the sun and other stars. But this new facility in China could be a sign China is starting to to edge ahead.
'It signals that they are serious about fusion' said Melanie Windridge, CEO of Fusion Energy Insights, an industry monitoring organization. 'They are being decisive, moving quickly and getting things done.'
Eveleth estimates China's Mianyang research center will be around 50% bigger than the United States' NIF and, once completed, likely the biggest facility of its kind in the world.
Its size could have advantages. A larger laser allows higher pressures and more material can be compressed, potentially increasing the energy achieved from nuclear fusion experiments, Appelbe told CNN. Although, he cautioned, achieving a successful fusion experiment is 'extremely challenging' even with a very large laser.
CNN contacted China's Ministries of National Defense and of Science and Technology for comment but had not heard back at the time of publication.
Experts say the facility also gives China the ability to research nuclear weapons.
China and the US are both parties to the Comprehensive Nuclear Test Ban Treaty, which prohibits nuclear explosions.
The level of energy unleashed by nuclear weapons is very difficult to simulate with computers and other conventional methods. This is where laser-ignition fusion facilities can help, Eveleth said. They can shine high-powered lasers onto various materials to simulate the conditions in the first few microseconds after a nuclear explosion.
'Any country with an NIF-type facility can and probably will be increasing their confidence and improving existing weapons designs,' William Alberque, a nuclear policy analyst at the Henry L. Stimson Centre, told Reuters.
A positive interpretation of the facility is that it provides reassurance China isn't planning any explosive nuclear testing, Eveleth said. But, he added, it could also allow them to develop more sophisticated designs, including smaller nuclear weapons.
Some experts believe the Mianyang site may end being a different kind of fusion facility, a hybrid of fusion and fission.
'If this proves to be true, it is particularly alarming,' said Andrew Holland, chief executive of the Fusion Industry Association. This would be homegrown Chinese tech and 'likely more powerful than anything of that type in Western countries.'
Regardless, the facility 'is clearly part of an ambitious program,' Holland told CNN.
The US is still ahead in the fusion race for now, he added, but 'China is moving fast' and has shown it can move from concept to completion much faster than any government programs.
'It is time to build, it is time to invest,' Holland said. 'If the US and its allies do not, then China will win this race.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift

Business Wire

timean hour ago

  • Business Wire

HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift

MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion," said Mike Blue, President and CEO, HistoSonics. The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:

Why has there been a global surge of new Covid variant NB.1.8.1?
Why has there been a global surge of new Covid variant NB.1.8.1?

Yahoo

time3 hours ago

  • Yahoo

Why has there been a global surge of new Covid variant NB.1.8.1?

India is the latest country to report a surge in new Covid cases, as the latest variant, NB.1.8.1, spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week. But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif. Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.

Why has there been a global surge of new Covid variant NB.1.8.1?
Why has there been a global surge of new Covid variant NB.1.8.1?

Yahoo

time4 hours ago

  • Yahoo

Why has there been a global surge of new Covid variant NB.1.8.1?

India is the latest country to report a surge in new Covid cases, as the latest variant, NB.1.8.1, spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week. But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif. Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store